摘要 湘雅医疗已推出脑机接口系列产品，包括脑电图机和搭载多模态技术的 新品，覆盖疾病诊疗和患者康复，预计 2026 年一季度将有 10 余款非 侵入式脑控产品取得注册证，并计划推出七八十款新产品，年底将有百 余款面市，加速产品迭代。 湘雅医疗的脑控产品已进入 500 多家头部医院，预计到 2027 年春节前 覆盖 1,000 余家，主要通过临床研究、科研项目或采购方式进入，并正 办理非侵入式脑机接口一体机注册，有望在 2026 年带来显著销售收入 提升。 新设备主要为二类医疗器械，无需临床试验，是对传统康复设备的升级， 加载脑机接口技术后实现主动康复，效果较传统被动康复提升 20%以上， 且这一比例还在不断提高，具有显著优势。 脑机接口设备在三甲医院等头部医院的需求和采购意愿强烈，各地政府 也出台相关产业政策支持，已有近 20 个省市公布了脑机接口相关收费 目录，推动了脑机接口设备在临床应用中的加速发展。 Q&A 请介绍一下湘雅医疗在脑机接口领域的最新进展和未来计划。 湘雅医疗在脑机接口领域的探索始于 2015 年，当时与天津大学现任副校长明 东教授联合申报了国家重点课题"脑机交互的康复机器人及脑控电刺激技术 ...

威高股份 20260107 摘要 威高股份拟重组，将控股威高洁净，实现与威高血液净化的协同效应， 并切入生物制药上游产业链，开启第二增长曲线。预计交易在 2026 年 六七月份完成。 威高普瑞作价 85.1 亿人民币，PE 倍数为 14.66 倍，高于同类上市企业 估值指标，但符合监管要求，并有业绩承诺。威高血液净化发行价格为 31.229 元每股，相当于最高折扣率 80%。 交易完成后，威高股份及其控制的员工持股平台将合计持有 52.10%的 威高血液净化，实现对其控股。威高集团对血液净化的直接持股比例将 大幅摊薄至 24.90%。 威高血液净化未来三年承诺按不低于当年实现净利润 50%进行分红，威 高系统上市平台将分红比例维持在 50%甚至更高，以增加投资者收益。 威高普瑞利用现有客户资源与中空纤维膜技术平台，开发生物制药上游 过滤产品，目标市场规模达全球 1,500 亿人民币，中国 210 亿人民币。 中国创新药行业 License out 和 BD 交易金额创新高，生物制药上游需 求急剧增长，国产替代机会显现，过滤器增速约为 11%~12%。 预计威高普瑞未来两到三年收入和净利润复合增长率在 10%以 ...

1月7日，威高血净跌2.17%，成交额1.53亿元。两融数据显示，当日威高血净获融资买入额1834.67万 元，融资偿还1608.79万元，融资净买入225.88万元。截至1月7日，威高血净融资融券余额合计1.46亿 元。 融资方面，威高血净当日融资买入1834.67万元。当前融资余额1.45亿元，占流通市值的9.00%。 截至9月30日，威高血净股东户数2.48万，较上期减少20.95%；人均流通股1535股，较上期增加 26.51%。2025年1月-9月，威高血净实现营业收入27.36亿元，同比增长3.45%；归母净利润3.41亿元，同 比增长7.92%。 分红方面，威高血净A股上市后累计派现6582.13万元。 责任编辑：小浪快报 融券方面，威高血净1月7日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量6300.00股，融券余额25.87万元。 资料显示，山东威高血液净化制品股份有限公司位于山东省威海火炬高技术产业开发区威高西路7号， 成立日期2004年12月27日，上市日期2025年5月19日，公司主营业务涉及血液净化医用制品的研发、生 产和销售。主营业务收入 ...

昨日中概股脑再生科技大涨60.1%，已连续拉出3根大阳线。此次脑机接口概念的爆发与特斯拉创始人马斯克近期的"量产预告"密切相关。马斯克的发言为脑 机接口技术的实际应用提供了重要信号，市场对此反响热烈，推动了脑机接口相关企业的股价上升，显示出投资者对这一新兴领域的浓厚兴趣和信心。 指数维度，医疗器械ETF(562600)跟踪的医疗器械指数脑机接口占比20.91%，在全市场指数中含量最高，指数自2021年7月至今调整周期已达4年半，调整幅 度超60%，价格已回到上一波行情启动位，具备风口初期，逢低布局的特征。 ...

智通财经APP获悉，中金发布研报称，考虑上游拓展仍需一定时间而普耗集采压力略高于1H25预期， 下调威高股份(01066) 25/26年净利润7%/7%至19.89/21.83亿元，引入27年净利润23.48亿元，当前股价对 应26/27年P/E为9.9/8.9x，考虑板块估值中枢上行，该行维持目标价6.40港元和跑赢行业评级不变，对应 26/27年P/E为12.1/11.3x，隐含22.4%上行空间。 中金主要观点如下： 2026年1月5日，威高股份公告与威高血净交易进展，换股交易对价合理，公司将控股威高血净 去年10月，威高股份和威高血净公告，威高血净计划向威高股份以发行股份方式获得威高股份子公司威 高普瑞股权。今年1月5日，威高股份公告确认威高普瑞作价最终对价为人民币85.11亿元（对应24年静 态P/E为14.66x），对价股份为2.72亿股，占威高血净当前已发行/扩大后总股数的65.11%/39.43%。交易 完成后，威高血净将持有100%威高普瑞股权，威高股份对血净持股比例将从23.53%升到51.35%，对普 瑞持股比例从94.07%变为间接持股51.35%，威高血净（并表威高普瑞）成为威高股份 ...

中金发布研报称，考虑上游拓展仍需一定时间而普耗集采压力略高于1H25预期，下调威高股份 (01066)25/26年净利润7%/7%至19.89/21.83亿元，引入27年净利润23.48亿元，当前股价对应26/27年P/E 为9.9/8.9x，考虑板块估值中枢上行，该行维持目标价6.40港元和跑赢行业评级不变，对应26/27年P/E为 12.1/11.3x，隐含22.4%上行空间。 中金主要观点如下： 2026年1月5日，威高股份公告与威高血净（603014）交易进展，换股交易对价合理，公司将控股威高血 净 风险提示：集采降价，新品推广不及预期，国际化不及预期，竞争格局恶化。 威高普瑞业绩承诺较为合理谨慎 威高股份承诺普瑞将在26-28年达到净利润分别为6.39/7.20/7.84亿元，复合增速10.7%。如交易实施完毕 的时间延后至2027年，则普瑞27-29年承诺净利润分别为7.20/7.84/8.45亿元，复合增速8.3%。 血净和普瑞具有协同效应，共同拓展生物制药上游大赛道 威高血净聚焦血液透析和腹膜透析的耗材和设备，具备透析膜术，已有滤器产品。威高普瑞专注于预灌 封给药系统及自动安全给药系统等面向疫 ...

Group 1 - The core viewpoint of the article highlights the successful debut of Precision Medical-B (02675) on the stock market, with a significant opening increase of 36.45% [1] - The company priced its shares at HKD 43.24, issuing a total of 27.72 million shares, resulting in a net proceeds of HKD 1.117 billion [1] - As of the report, the stock was trading at HKD 59, with a transaction volume of HKD 188 million [1] Group 2 - Precision Medical is recognized as an advanced surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - According to Frost & Sullivan, the company is the first in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - Financial projections indicate revenues of approximately HKD 48.04 million, HKD 160 million, and HKD 150 million for the years 2023, 2024, and the first half of 2025, respectively, with expected losses of around HKD 213 million, HKD 219 million, and HKD 89.087 million [1] Group 3 - According to Founder Securities, the global IPO of Precision Medical has attracted diverse and global cornerstone investors, reigniting capital interest in the laparoscopic robot sector [2] - The current penetration rate of laparoscopic surgical robots in China is less than 1%, significantly lower than the 21.9% in the United States, indicating substantial room for growth in domestic market share [2] - The market is predominantly led by the Da Vinci system, which holds over 40% of the market share, suggesting opportunities for increased domestic production [2]

Core Viewpoint - Jingfeng Medical-B (02675) has successfully listed, with shares priced at HKD 43.24, raising a net amount of HKD 1.117 billion, and has seen a significant increase of 36.45% to HKD 59 per share at the time of reporting [1] Company Summary - Jingfeng Medical is a leading surgical robot company in China's medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - It is the first company in China and the second globally to obtain regulatory approval for multi-port, single-port, and natural orifice surgical robots [1] - Financial projections indicate revenues of HKD 48.04 million, HKD 160 million, and HKD 150 million for the years 2023, 2024, and the first half of 2025, respectively, with expected losses of approximately HKD 213 million, HKD 219 million, and HKD 89.087 million for the same periods [1] Industry Summary - According to Fangzheng Securities, the global IPO of Jingfeng Medical has attracted diverse and global cornerstone investors, reigniting capital interest in the laparoscopic robot sector [1] - The current penetration rate of laparoscopic surgical robots in China is less than 1%, significantly lower than the 21.9% in the United States, indicating substantial room for growth in domestic market share [1] - The market is predominantly led by the Da Vinci system, which holds over 40% of the market share, suggesting a strong potential for increased domestic production [1] - Continuous support from national policies and an accelerated opening of configuration licenses are contributing to the growing interest in this sector within the capital markets [1]

Group 1 - The stock of Kangtong Medical (301515) closed at 21.23 yuan on January 7, 2026, down 3.85%, with a turnover rate of 8.43% and a trading volume of 55,300 hands, resulting in a transaction amount of 119 million yuan [1] - On January 7, the net outflow of main funds was 12.1 million yuan, accounting for 10.2% of the total transaction amount, while retail funds saw a net inflow of 2.8 million yuan, representing 2.36% of the total transaction amount [1] - The financing data for Kangtong Medical shows a financing buy of 10.94 million yuan and a financing repayment of 14.57 million yuan, resulting in a net repayment of 3.62 million yuan [2] Group 2 - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06%, and a net profit attributable to shareholders of -10.21 million yuan, down 150.92% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 79.12 million yuan, an increase of 42.81% year-on-year, but the net profit attributable to shareholders was -1.80 million yuan, a decline of 138.94% [3] - The company's debt ratio stands at 40.94%, with an investment income of -179,400 yuan and financial expenses of 542,400 yuan, while the gross profit margin is 22.45% [3]

南财投研通数据显示，1月7日，券商给予上市公司目标价共4次，按最新收盘价计算，目标价涨幅排名居前的公司有众 鑫股份（603091）、瑞迈特（301367）、环旭电子（601231），目标价涨幅分别为28.45%、20.80%、11.07%，分别属 于包装印刷、医疗器械、消费电子行业。 | | | 01月07日目标价涨幅排名 | | | | | --- | --- | --- | --- | --- | --- | | 证券代码 | 证券名称 | 机构 | 最新评级 | 最高目标价 | 目标涨幅 | | | | | | (元) | (%) | | 603091 | 众鑫股份 | 国泰海通证券 | 增持 | 99.68 | 28.45 | | 301367 | 瑞迈特 | 中国国际金融 | 跑赢行业 | 110.00 | 20.80 | | 601231 | 环関电子 | 中信证券 | 买人 | 33.00 | 11.07 | | 600167 | 联美控股 | 国投证券 | 增持 | 7.35 | 2.80 | | | | 日期: 01月07日,南财投研通×南财快讯制图 | | | | | 证券代码 | 证券名 ...